Portfolio Companies News
March 12, 2018Strongbridge Biopharma plc Reports ...
~ KEVEYIS®(dichlorphenamide) Fourth Quarter and Full-Year 2017 Revenue of $3.0 Million and $7.0 Million, Respectively ~ ~ Full-Year 2018 KEVEYIS Revenue Guidance of $16 to $19 Million ~ ~ MACRILEN™ (macimorelin) Product Launch on Track for Mid-2018 ~ ~ RECORLEV™ (levoketoconazole) Pha... read more
March 12, 2018Nordic Nanovector to Present at the...
12.03.2018 07:00 Oslo, Norway, 12 March 2018 Nordic Nanovector ASA (OSE: NANO) announces that the company will be presenting at the following upcoming investor conferences: • The China Healthcare Investing & Partnering Symposium (CHIPS) in Hangzhou, China (15-17 March) •... read more
March 12, 2018Altimmune Announces Pre-Clinical Da...
Single dose of vaccine showed 67% survival rate and 100% survival rate after two doses GAITHERSBURG, Md., March 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced data from a pre-clinical study comparing SparVax-L and BioThrax® a... read more
March 12, 2018Wilson Therapeutics announces agend...
Mar 12, 2018 Wilson Therapeutics (publ) is pleased to announce the agenda for its Capital Markets Day to be held in Stockholm on Wednesday 21 March 2018. Members of the senior management team will be joined by Dr. Frederick K. Askari MD, PhD, Associate Professor and Director of the Wilson Dise... read more
March 7, 2018Strongbridge Biopharma Investor and...
Please join us for Strongbridge Biopharma’s Investor and Analyst Day taking place on Thursday, April 5, 2018 in New York City. The event will include presentations from the Senior Management Team at Strongbridge Biopharma, as well as leading KOLs, Dr. Richard Auchus, Dr. Beverly MK Biller and D... read more
February 07, 2018Q4 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 110 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.